The following chart summarizes some difference between the three countries. Notice that the reported rates of chlamydia are lower than the true rates due to under reporting. In addition, higher rates does not suggest a policy failure, since increased screening rates will results in higher the rates of reported cases. Table 1: Summary of Differences Between the three Countries US UK China Insurance System Multiple public payer Universal coverage; Single public payer system, no universal single public payer system; coverage; system reimbursement varies reimbursement varies in in each provinces each state Mandatory Reporting Yes Yes No Opt-out approach No Yes No Test and Treatment Cost Varies by different Free screening and Varies by different providers and insurance treatment from providers and benefits government-funded insurance benefits clinics and programs Screening Rate About 50% among 16% young adults Unknown commercial and under 25 years old Medicaid plans insured population Reported Rate Greater than 456.7 Greater than 2,300 Inconsistence data cases per 100,000 per 100,000 among due to lack of (total) 15 to 24 year surveillance: 6.04% to 13.4% among —0.457% women Diagnostic Test Recommended: NAAT; Recommended: Unspecified also used some EIA and NAAT; also use recommendation; DFA some EIA and DFA EIA and DFA are the main assays of choice Treatment Doxycycline or Doxycycline or Doxycycline or Azithromycin and other Azithromycin and Azithromycin and other other
The following chart summarizes some difference between the three countries. Notice that the reported rates of chlamydia are lower than the true rates due to under reporting. In addition, higher rates does not suggest a policy failure, since increased screening rates will results in higher the rates of reported cases. Table 1: Summary of Differences Between the three Countries US UK China Insurance System Multiple public payer system, no universal coverage; reimbursement varies in each state Universal coverage; single public payer system Single public payer system; reimbursement varies in each provinces Mandatory Reporting Yes Yes No Opt-out approach No Yes No Test and Treatment Cost Varies by different providers and insurance benefits Free screening and treatment from government-funded clinics and programs Varies by different providers and insurance benefits Screening Rate About 50% among commercial and Medicaid plans insured population 16% young adults under 25 years old Unknown Reported Rate Greater than 456.7 cases per 100,000 (total) —0.457% Greater than 2,300 per 100,000 among 15 to 24 year Inconsistence data due to lack of surveillance: 6.04% to 13.4% among women Diagnostic Test Recommended: NAAT; also used some EIA and DFA Recommended: NAAT; also use some EIA and DFA Unspecified recommendation; EIA and DFA are the main assays of choice Treatment Doxycycline or Azithromycin and other Doxycycline or Azithromycin and other Doxycycline or Azithromycin and other
Wanyue_Chen_mph_4_2016.docx